Final Height in Patients with Turner Syndrome Treated With Growth Hormone Therapy

Objective: Turner syndrome (TS) is the most common sex chromosome abnormality in girls. Short stature is the most distinctive feature. This study aimed to evaluate factors affecting final height (FH) in patients with TS who received growth hormone (GH) therapy and achieved their f inal height (FH). Materials and

Methods: About 48 patients with TS who received GH therapy and reached their FH were included and examined retrospectively. Initial height, standard deviation score (SDS), FH, and FH SDS measurements of the patients were obtained. Additionally, factors affecting FH were analyzed.

Results: Growth hormone was administered at a dose of 45.6 ± 6.2 (min-max: 34-69) μg/kg/ day at a mean age of 11.7 ± 2.9 years. The duration of therapy was 4.3 ± 1.4 years. The mean FH of the patients was 147.80 ± 5.98 cm. About 29.2% (n = 14) of the patients reached a height above the thirdpercentile. It was observed that GH therapy was initiated in these patients at a mean age of 10.3 ± 3.1 years; the initial height SDS was better. FH of 45,X and non-45,X cases were similar.

Conclusion: In the study, GH therapy that was initiated at an early age in patients with good initial height SDS increased the gain of FH and FH SDS. Therefore, initiating GH therapy at an early age in patients with TS is important for height gain. ∆ Height SDS was better in cases that underwent late pubertal induction. Karyotype did not have a predictive effect on height prognosis.

Cite this article as: Karakaya AA, Unal E, Yıldırım R, Özalkak Ş, Taş FF, Özbek MN. Final height in patients with Turner syndrome who received growth hormone therapy. Turk Arch Pediatr. Published online December 22, 2025. doi:10.5152/TurkArchPediatr.2025.25132.